What's breaking now, across thousands of outlets.
Key PointsAxsome Therapeutics' revenue is growing at a good clip.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
The peso's remarkable run had been losing stream recently anyway, but the U.S. Federal Reserve's decision to raise U.S. interest rates served as a solid wall on the Mexican currency.
CNBC’s Jim Cramer said investors could be in for a relatively quiet week as Wall Street works its way through a historically difficult September.
Investment in gold has long been regarded as a hedge against economic uncertainty, particularly during periods of heightened volatility.
Spaceships with tentacles. Designing an award-winning drug. How the Fed hiking rates will impact emerging tech. All that and more in this week’s Prototype.
Key PointsPfizer has a deep pipeline that could help improve its approved lineup and financial results over the medium term.
You may be able to profit from investors’ irrational belief that crashes are especially likely to occur in October.
